Roivant Sciences Ltd. [ROIV] CEO makes an insider sale of 20,455 shares worth 88,570.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Roivant Sciences Ltd. shares valued at $88,570 were sold by Gline Matthew on Jul 25. At $4.33 per share, Gline Matthew sold 20,455 shares. The insider’s holdings dropped to 1,224,347 shares worth approximately $4.65 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Kumar Rakhi sold 1,686 shares, netting a total of over 7,300 in proceeds. Following the sale of shares at $4.33 each, the insider now holds 144,335 shares.

Before that, Venker Eric had sold 16,896 shares from its account. In a trade valued at $73,160, the President & COO traded Roivant Sciences Ltd. shares for $4.33 each. Upon closing the transaction, the insider’s holdings decreased to 16,896 shares, worth approximately $4.18 million.

As published in their initiating research note from SVB Leerink on May 23, 2022, Roivant Sciences Ltd. [ROIV] has been an Outperform and the price target has been revised to $6. This represents a 36.67% premium over Thursday’s closing price. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of December 15, 2021, Goldman has initiated its “Buy” rating for ROIV. Earlier on November 08, 2021, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for ROIV stock.

Analyzing ROIV’s Price Performance

On Thursday, Roivant Sciences Ltd. [NASDAQ: ROIV] rose 0.26% to $3.80. The stock’s lowest price that day was $3.73, but it reached a high of $3.85 in the same session. During the last five days, there has been a drop of approximately -7.99%. Over the course of the year, Roivant Sciences Ltd. shares have dropped approximately -62.30%. A 50-day SMA is recorded $4.23, while a 200-day SMA reached $6.05. Nevertheless, trading volume fell to 1.01 million shares from 0.73 million shares the previous day.

Support And Resistance Levels for Roivant Sciences Ltd. (ROIV)

According to the 24-hour chart, there is a support level at 3.74, which, if violated, would cause prices to drop to 3.67. In the upper region, resistance lies at 3.86. The next price resistance is at 3.91. RSI (Relative Strength Index) is 39.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.34, which suggests the price will decrease in the coming days. Percent R is at 79.79%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Roivant Sciences Ltd. subject to short interest?

Stocks of Roivant Sciences Ltd. saw a sharp rise in short interest on Jul 14, 2022 jumping by 2.2 million shares to 8.15 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 5.95 million shares. A jump of 26.99% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.18 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.18.

Which companies own the most shares of Roivant Sciences Ltd. (ROIV)?

According to QVT Financial LP filings, the company currently owns 129,393,817 shares, which is about 18.47% of the total ROIV shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 129393817.0 shares. With the completion of the sale transaction, Viking Global Investors LP’s stake is now worth $359,131,509. A total of 3,000,000 shares of Roivant Sciences Ltd. were bought by Bluecrest Capital Management LLP during the quarter, and 0 were sold by Fidelity Management & Research Co. In its current portfolio, AIG Asset Management holds 1,814,697 shares valued at $7.39 million.

In terms of Roivant Sciences Ltd. share price expectations, FactSet research, analysts set an average price target of $11.57 in the next 12 months, up nearly 243.01% from the previous closing price of $3.79. Analysts anticipate Roivant Sciences Ltd. stock to reach $16.00 by 2022, with the lowest price target being $7.00. In spite of this, 8 analysts ranked Roivant Sciences Ltd. stock as a Buy at the end of 2022. On October 28, 2021, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $11.


Please enter your comment!
Please enter your name here